Abeona Therapeutics Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDAbeona Therapeutics Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 58), indicating performance broadly in line with the market. Earnings contraction of 25% provides fundamental context to the price action. Investors should exercise caution due to high volatility (51% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $5.61 | +0.91% | ABOVE |
| 50 SMA | $5.59 | +1.32% | ABOVE |
| 100 SMA | $5.25 | +7.81% | ABOVE |
| 150 SMA | $5.20 | +8.78% | ABOVE |
| 200 SMA | $5.20 | +8.79% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ABEO in an uptrend right now?
ABEO has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, ABEO is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is ABEO overbought or oversold?
ABEO's RSI (14) is 51. The stock is in neutral territory, neither overbought nor oversold.
Is ABEO outperforming the market?
ABEO has a Relative Strength (RS) Rating of 58 out of 99. ABEO is performing about average compared to the market.
Where is ABEO in its 52-week range?
ABEO is trading at $5.66, which is 75% of its 52-week high ($7.54) and 47% above its 52-week low ($4.00).
How volatile is ABEO?
ABEO has a Beta of 1.46 and 52-week volatility of 51%. It's more volatile than the S&P 500 - expect bigger swings.